SCHEMBL4129697

SCHEMBL4129697

O=C(Cc1ccc(NC2=NC(=O)/C(=C\c3ccc(-c4ccccc4)cc3)S2)cc1)NO

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 9/20 0.45
HDAC8 Q9BY41 3/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
PDE4B Q07343 1/20 0.45
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
AKR1B1 P15121 1/20 0.39
NLRP3 Q96P20 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4129701 1.00 ALOX5 (0.45) ALOX5HDAC8HDAC6HDAC1HDAC3
SCHEMBL4132445 0.90 FFAR1 (0.47) ALOX5PDE4BAKR1B1
SCHEMBL4132443 0.90 FFAR1 (0.47) ALOX5PDE4BAKR1B1
SCHEMBL4137078 0.88 PDE4B (0.45) ALOX5PDE4BAKR1B1NLRP3
SCHEMBL4133729 0.87 PDE4B (0.49) ALOX5PDE4BKMT2AMEN1AKR1B1
SCHEMBL4133731 0.87 PDE4B (0.49) ALOX5PDE4BKMT2AMEN1AKR1B1
SCHEMBL4141291 0.84 ALOX5 (0.44) ALOX5KMT2AMEN1AKR1B1NLRP3
SCHEMBL4141289 0.84 ALOX5 (0.44) ALOX5KMT2AMEN1AKR1B1NLRP3
SCHEMBL4133860 0.83 DUSP22 (0.49) ALOX5PDE4BAKR1B1
SCHEMBL4133862 0.83 DUSP22 (0.49) ALOX5PDE4BAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885HDAC8 2162/4885HDAC6 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.